OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

OBI's company English name official renamed OBI Pharma, Inc.

Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD